FOUNDAYO - (EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET)

Generic Name	ORFORGLIPRON CALCIUM	**Innovator**	None
Dosage	EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.